(function(){var loadHandler=window['sl_{656BC694-C0A1-4D3A-883A-292145561588}'];loadHandler&&loadHandler(9, '<div id="spr0_3a3bc79"><div id="spr1_3a3bc79" class="kern slide"><img id="img0_3a3bc79" src="data/img5.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/><div id="svg6_3a3bc79" style="left:49.06px;top:94.123px;"><svg width="1182" height="3" viewBox="-1.333 -0.667 1182 3"><g fill="#c2b6ab" stroke="none"><path stroke="#c2b6ab" stroke-width="1.333" stroke-linecap="butt" transform="translate(-50.393677,-94.789497)" d="M50.394,95.456 H1229.606"/></g></svg></div><div id="svg9_3a3bc79" style="left:49.06px;top:94.123px;"><svg width="1182" height="3" viewBox="-1.333 -0.667 1182 3"><g fill="#cdd7dc" stroke="none"><path stroke="#cdd7dc" stroke-width="1.333" stroke-linecap="butt" transform="translate(-50.393677,-94.789497)" d="M50.394,95.456 H1229.606"/></g></svg></div></div><div id="spr2_3a3bc79" class="kern slide"><div id="spr3_3a3bc79" style="left:39.366px;top:24.21px;"><div style="width:0px;"><span id="txt0_3a3bc79" data-width="427.833344" style="top:-0.696px;">Why ToxNav (DPYD test)?</span></div></div><div id="spr4_3a3bc79" style="left:39.366px;top:131.163px;"><div style="width:0px;"><span id="txt1_3a3bc79" class="nokern relpos" dir="auto" style="top:42.623px;">•</span> <span id="txt2_3a3bc79" class="relpos" data-width="1157.096313" style="left:26.664px;top:42.747px;">4 genomic variants in the DPYD gene are tested for, but 50% of patients with severe toxicity do not</span></div><div style="width:0px;"><span id="txt3_3a3bc79" data-width="135.247391" style="left:36px;top:81.147px;">carry them.</span></div><div style="width:0px;"><span id="txt4_3a3bc79" class="nokern relpos" dir="auto" style="top:157.823px;">•</span> <span id="txt5_3a3bc79" class="relpos" data-width="1124.140625" style="left:26.664px;top:157.947px;">ToxNav was developed to allow for testing a broader panel of variants that may have correlation</span></div><div style="width:0px;"><span id="txt6_3a3bc79" data-width="1102.500000" style="left:36px;top:196.347px;">with 5FU and capecitabine toxicities. These included three of the four CPIC variants, 15 DPYD</span></div><div style="width:0px;"><span id="txt7_3a3bc79" data-width="966.861938" style="left:36px;top:234.747px;">additional variants, and one Enolase Superfamily Member 1 (ENOSF1) gene allele.</span></div><div style="width:0px;"><span id="txt8_3a3bc79" class="nokern relpos" dir="auto" style="top:311.423px;">•</span> <span id="txt9_3a3bc79" class="relpos" data-width="1149.387939" style="left:26.664px;top:311.547px;">Identifying poor metabolisers prior to chemotherapy would allow for dose adjustment, potentially</span></div><div style="width:0px;"><span id="txt10_3a3bc79" data-width="301.953125" style="left:36px;top:349.947px;">avoiding severe toxicities.</span></div></div><div id="spr5_3a3bc79" style="left:1128.819px;top:682.205px;"><div style="width:0px;"><span id="txt11_3a3bc79" class="nokern" data-width="13.912760" style="left:86.933px;top:0.686px;">10</span></div></div></div></div>', '{"s":[]}');})();